Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSCs for Post-Acute COVID-19 Depression
NCT05346120Phase 2Withdrawn
- Start
- May 2022
- Primary completion
- Dec 2023
- Modality
- Stem Cell Therapies
01
Overview
A Phase 2 trial of allogeneic bone marrow-derived mesenchymal stromal cells in major depressive disorder (MDD). Planned start May 2022; status: withdrawn.
02
Drugs
allogeneic bone marrow-derived mesenchymal stromal cells
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05346120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05346120.